The human papillomavirus E6 oncoprotein targets USP15 and TRIM25 to suppress RIG-I-mediated innate immune signaling

Journal of Virology

Volumn 92, Issue 6, 2018, Pages

  Chiang, Cindy ^a   Pauli, Eva Katharina ^b   Biryukov, Jennifer ^c   Feister, Katharina F ^b   Meng, Melissa ^b   White, Elizabeth A ^d   Münger, Karl ^e   Howley, Peter M ^b   Meyers, Craig ^b   Gack, Michaela U ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Innate immunity; Interferons; Papillomavirus; RIG I

Indexed keywords

ADAPTOR PROTEIN; BETA INTERFERON; BINDING PROTEIN; N TERMINAL TANDEM CASPASE ACTIVATION AND RECRUITMENT DOMAIN PROTEIN; PROTEIN E6; PROTEIN MAVS; PROTEIN TRIM25; RETINOIC ACID INDUCIBLE PROTEIN I; UBIQUITIN SPECIFIC PROTEASE 15; UNCLASSIFIED DRUG; VIRUS ENZYME; DDX58 PROTEIN, HUMAN; DEUBIQUITINASE; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6; ONCOPROTEIN; TRANSCRIPTION FACTOR; TRIM25 PROTEIN, HUMAN; TRIPARTITE MOTIF PROTEIN; UBIQUITIN PROTEIN LIGASE; USP15 PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; CRISPR-CAS9 SYSTEM; ENZYME DEGRADATION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; INNATE IMMUNITY; KERATINOCYTE; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UBIQUITINATION; GENETICS; HEK293 CELL LINE; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOLOGY; PATHOLOGY; VIROLOGY;

DEAD BOX PROTEIN 58; HEK293 CELLS; HUMAN PAPILLOMAVIRUS 6; HUMANS; IMMUNITY, INNATE; KERATINOCYTES; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRIPARTITE MOTIF PROTEINS; UBIQUITIN-PROTEIN LIGASES; UBIQUITIN-SPECIFIC PROTEASES;

EID: 85042464490     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01737-17     Document Type: Article

References (73)

1. Sparrer KM, Gack MU. 2015. Intracellular detection of viral nucleic acids. Curr Opin Microbiol 26:1-9. https://doi.org/10.1016/j.mib.2015.03.001
2. Takeuchi O, Akira S. 2010. Pattern recognition receptors and inflammation. Cell 140:805-820. https://doi.org/10.1016/j.cell.2010.01.022
3. Goubau D, Schlee M, Deddouche S, Pruijssers AJ, Zillinger T, Goldeck M, Schuberth C, Van der Veen AG, Fujimura T, Rehwinkel J, Iskarpatyoti JA, Barchet W, Ludwig J, Dermody TS, Hartmann G, Reis ESC. 2014. Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5'-diphosphates. Nature 514:372-375. https://doi.org/10.1038/nature13590
4. Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, Kato H, Poeck H, Akira S, Conzelmann KK, Schlee M, Endres S, Hartmann G. 2006. 5'-Triphosphate RNA is the ligand for RIG-I. Science 314:994-997. https://doi .org/10.1126/science.1132505
5. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu S, Jung A, Kawai T, Ishii KJ, Yamaguchi O, Otsu K, Tsujimura T, Koh CS, Reis e Sousa C, Matsuura Y, Fujita T, Akira S. 2006. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441:101-105. https://doi.org/10.1038/nature04734
6. Pichlmair A, Schulz O, Tan CP, Naslund TI, Liljestrom P, Weber F, Reis e Sousa C. 2006. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science 314:997-1001. https://doi.org/10 .1126/science.1132998
7. Dempsey A, Bowie AG. 2015. Innate immune recognition of DNA: a recent history. Virology 479-480:146-152
8. Paz S, Sun Q, Nakhaei P, Romieu-Mourez R, Goubau D, Julkunen I, Lin R, Hiscott J. 2006. Induction of IRF-3 and IRF-7 phosphorylation following activation of the RIG-I pathway. Cell Mol Biol (Noisy-le-Grand) 52:17-28
9. Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, Ishii KJ, Takeuchi O, Akira S. 2005. IPS-1, an adaptor triggering RIG-I-and Mda5-mediated type I interferon induction. Nat Immunol 6:981-988. https://doi.org/10 .1038/ni1243
10. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, Tschopp J. 2005. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437:1167-1172. https://doi.org/10.1038/nature04193
11. Seth RB, Sun L, Ea CK, Chen ZJ. 2005. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NFkappaB and IRF 3. Cell 122:669-682. https://doi.org/10.1016/j.cell.2005 .08.012
12. Xu LG, Wang YY, Han KJ, Li LY, Zhai Z, Shu HB. 2005. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol Cell 19: 727-740. https://doi.org/10.1016/j.molcel.2005.08.014
13. Chiang C, Gack MU. 2017. Posttranslational control of intracellular pathogen sensing pathways. Trends Immunol 38:39-52. https://doi.org/10 .1016/j.it.2016.10.008
14. Gack MU, Kirchhofer A, Shin YC, Inn KS, Liang C, Cui S, Myong S, Ha T, Hopfner KP, Jung JU. 2008. Roles of RIG-I N-terminal tandem CARD and splice variant in TRIM25-mediated antiviral signal transduction. Proc Natl Acad Sci U S A 105:16743-16748. https://doi.org/10.1073/ pnas.0804947105
15. Gack MU, Shin YC, Joo CH, Urano T, Liang C, Sun L, Takeuchi O, Akira S, Chen Z, Inoue S, Jung JU. 2007. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 446:916-920. https://doi.org/10.1038/nature05732
16. Jiang X, Kinch LN, Brautigam CA, Chen X, Du F, Grishin NV, Chen ZJ. 2012. Ubiquitin-induced oligomerization of the RNA sensors RIG-I and MDA5 activates antiviral innate immune response. Immunity 36: 959-973. https://doi.org/10.1016/j.immuni.2012.03.022
17. Peisley A, Wu B, Xu H, Chen ZJ, Hur S. 2014. Structural basis for ubiquitin-mediated antiviral signal activation by RIG-I. Nature 509: 110-114. https://doi.org/10.1038/nature13140
18. Sanchez JG, Chiang JJ, Sparrer KM, Alam SL, Chi M, Roganowicz MD, Sankaran B, Gack MU, Pornillos O. 2016. Mechanism of TRIM25 catalytic activation in the antiviral RIG-I pathway. Cell Rep 16:1315-1325. https:// doi.org/10.1016/j.celrep.2016.06.070
19. Inn KS, Gack MU, Tokunaga F, Shi M, Wong LY, Iwai K, Jung JU. 2011. Linear ubiquitin assembly complex negatively regulates RIG-I-and TRIM25-mediated type I interferon induction. Mol Cell 41:354-365. https://doi.org/10.1016/j.molcel.2010.12.029
20. Pauli EK, Chan YK, Davis ME, Gableske S, Wang MK, Feister KF, Gack MU. 2014. The ubiquitin-specific protease USP15 promotes RIG-I-mediated antiviral signaling by deubiquitylating TRIM25. Sci Signal 7:ra3. https:// doi.org/10.1126/scisignal.2004577
21. Vos RM, Altreuter J, White EA, Howley PM. 2009. The ubiquitin-specific peptidase USP15 regulates human papillomavirus type 16 E6 protein stability. J Virol 83:8885-8892. https://doi.org/10.1128/JVI.00605-09
22. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA. 2012. The biology and life-cycle of human papillomaviruses. Vaccine 30(Suppl 5):F55-F70. https://doi.org/10.1016/j.vaccine.2012.06.083
23. McBride AA. 2017. Mechanisms and strategies of papillomavirus replication. Biol Chem 398:919-927. https://doi.org/10.1515/hsz-2017-0113
24. Galloway DA, Laimins LA. 2015. Human papillomaviruses: shared and distinct pathways for pathogenesis. Curr Opin Virol 14:87-92. https://doi .org/10.1016/j.coviro.2015.09.001
25. Groves IJ, Coleman N. 2015. Pathogenesis of human papillomavirusassociated mucosal disease. J Pathol 235:527-538. https://doi.org/10 .1002/path.4496
26. Moody CA, Laimins LA. 2010. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 10:550-560. https://doi.org/10 .1038/nrc2886
27. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT. 1989. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 8:3905-3910
28. Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R. 1989. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 63:4417-4421
29. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. 1993. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495-505. https://doi.org/10.1016/0092-8674(93)90384-3
30. Boyer SN, Wazer DE, Band V. 1996. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 56:4620-4624
31. Huh K, Zhou X, Hayakawa H, Cho JY, Libermann TA, Jin J, Harper JW, Munger K. 2007. Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. J Virol 81: 9737-9747. https://doi.org/10.1128/JVI.00881-07
32. White EA, Sowa ME, Tan MJ, Jeudy S, Hayes SD, Santha S, Munger K, Harper JW, Howley PM. 2012. Systematic identification of interactions between host cell proteins and E7 oncoproteins from diverse human papillomaviruses. Proc Natl Acad Sci U S A 109:E260-E267. https://doi .org/10.1073/pnas.1116776109
33. White EA, Munger K, Howley PM. 2016. High-risk human papillomavirus E7 proteins target PTPN14 for degradation. mBio 7:e01530-16. https:// doi.org/10.1128/mBio.01530-16
34. Beglin M, Melar-New M, Laimins L. 2009. Human papillomaviruses and the interferon response. J Interferon Cytokine Res 29:629-635. https:// doi.org/10.1089/jir.2009.0075
35. Hong S, Laimins LA. 2017. Manipulation of the innate immune response by human papillomaviruses. Virus Res 231:34-40. https://doi.org/10 .1016/j.virusres.2016.11.004
36. Westrich JA, Warren CJ, Pyeon D. 2017. Evasion of host immune defenses by human papillomavirus. Virus Res 231:21-33. https://doi.org/10.1016/ j.virusres.2016.11.023
37. Hasan UA, Bates E, Takeshita F, Biliato A, Accardi R, Bouvard V, Mansour M, Vincent I, Gissmann L, Iftner T, Sideri M, Stubenrauch F, Tommasino M. 2007. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 178: 3186-3197. https://doi.org/10.4049/jimmunol.178.5.3186
38. Lau L, Gray EE, Brunette RL, Stetson DB. 2015. DNA tumor virus oncogenes antagonize the cGAS-STING DNA-sensing pathway. Science 350: 568-571. https://doi.org/10.1126/science.aab3291
39. Karim R, Meyers C, Backendorf C, Ludigs K, Offringa R, van Ommen GJ, Melief CJ, van der Burg SH, Boer JM. 2011. Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. PLoS One 6:e17848. https://doi.org/ 10.1371/journal.pone.0017848
40. Chan YK, Gack MU. 2016. Viral evasion of intracellular DNA and RNA sensing. Nat Rev Microbiol 14:360-373. https://doi.org/10.1038/nrmicro .2016.45
41. Vande Pol SB, Klingelhutz AJ. 2013. Papillomavirus E6 oncoproteins. Virology 445:115-137. https://doi.org/10.1016/j.virol.2013.04.026
42. Hetfeld BK, Helfrich A, Kapelari B, Scheel H, Hofmann K, Guterman A, Glickman M, Schade R, Kloetzel PM, Dubiel W. 2005. The zinc finger of the CSN-associated deubiquitinating enzyme USP15 is essential to rescue the E3 ligase Rbx1. Curr Biol 15:1217-1221. https://doi.org/10.1016/ j.cub.2005.05.059
43. Meyers C, Frattini MG, Hudson JB, Laimins LA. 1992. Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science 257:971-973. https://doi.org/10.1126/science.1323879
44. McLaughlin-Drubin ME, Christensen ND, Meyers C. 2004. Propagation, infection, and neutralization of authentic HPV16 virus. Virology 322: 213-219. https://doi.org/10.1016/j.virol.2004.02.011
45. Karim R, Tummers B, Meyers C, Biryukov JL, Alam S, Backendorf C, Jha V, Offringa R, van Ommen GJ, Melief CJ, Guardavaccaro D, Boer JM, van der Burg SH. 2013. Human papillomavirus (HPV) upregulates the cellular deubiquitinase UCHL1 to suppress the keratinocyte's innate immune response. PLoS Pathog 9:e1003384. https://doi.org/10.1371/journal.ppat .1003384
46. Urano T, Saito T, Tsukui T, Fujita M, Hosoi T, Muramatsu M, Ouchi Y, Inoue S. 2002. Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature 417:871-875. https://doi.org/10.1038/ nature00826
47. Sun N, Xue Y, Dai T, Li X, Zheng N. 2017. Tripartite motif containing 25 promotes proliferation and invasion of colorectal cancer cells through TGF-beta signaling. Biosci Rep 37:BSR20170805. https://doi.org/10.1042/ BSR20170805
48. Zhang P, Elabd S, Hammer S, Solozobova V, Yan H, Bartel F, Inoue S, Henrich T, Wittbrodt J, Loosli F, Davidson G, Blattner C. 2015. TRIM25 has a dual function in the p53/Mdm2 circuit. Oncogene 34:5729-5738. https://doi.org/10.1038/onc.2015.21
49. Zhu Z, Wang Y, Zhang C, Yu S, Zhu Q, Hou K, Yan B. 2016. TRIM25 blockade by RNA interference inhibited migration and invasion of gastric cancer cells through TGF-beta signaling. Sci Rep 6:19070. https://doi .org/10.1038/srep19070
50. Steinbach A, Riemer AB. 2017. Immune evasion mechanisms of human papillomavirus: an update. Int J Cancer 142:224-229. https://doi.org/10 .1002/ijc.31027
51. Bergot AS, Ford N, Leggatt GR, Wells JW, Frazer IH, Grimbaldeston MA. 2014. HPV16-E7 expression in squamous epithelium creates a local immune suppressive environment via CCL2-and CCL5-mediated recruit ment of mast cells. PLoS Pathog 10:e1004466. https://doi.org/10.1371/ journal.ppat.1004466
52. Chang YE, Laimins LA. 2000. Microarray analysis identifies interferoninducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J Virol 74:4174-4182. https://doi.org/10.1128/ JVI.74.9.4174-4182.2000
53. Park JS, Kim EJ, Kwon HJ, Hwang ES, Namkoong SE, Um SJ. 2000. Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem 275:6764-6769
54. Perea SE, Massimi P, Banks L. 2000. Human papillomavirus type 16 E7 impairs the activation of the interferon regulatory factor-1. Int J Mol Med 5:661-666
55. Reiser J, Hurst J, Voges M, Krauss P, Munch P, Iftner T, Stubenrauch F. 2011. High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression. J Virol 85:11372-11380. https://doi.org/ 10.1128/JVI.05279-11
56. Ronco LV, Karpova AY, Vidal M, Howley PM. 1998. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 12:2061-2072. https://doi.org/10 .1101/gad.12.13.2061
57. Goubau D, Deddouche S, Reis e Sousa C. 2013. Cytosolic sensing of viruses. Immunity 38:855-869. https://doi.org/10.1016/j.immuni.2013.05 .007
58. Zevini A, Olagnier D, Hiscott J. 2017. Crosstalk between cytoplasmic RIG-I and STING sensing pathways. Trends Immunol 38:194-205. https://doi .org/10.1016/j.it.2016.12.004
59. Liu Y, Goulet ML, Sze A, Hadj SB, Belgnaoui SM, Lababidi RR, Zheng C, Fritz JH, Olagnier D, Lin R. 2016. RIG-I-mediated STING upregulation restricts herpes simplex virus 1 infection. J Virol 90:9406-9419. https:// doi.org/10.1128/JVI.00748-16
60. Ablasser A, Bauernfeind F, Hartmann G, Latz E, Fitzgerald KA, Hornung V. 2009. RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat Immunol 10: 1065-1072. https://doi.org/10.1038/ni.1779
61. Chiu YH, Macmillan JB, Chen ZJ. 2009. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell 138:576-591. https://doi.org/10.1016/j.cell.2009.06.015
62. Rasmussen SB, Jensen SB, Nielsen C, Quartin E, Kato H, Chen ZJ, Silverman RH, Akira S, Paludan SR. 2009. Herpes simplex virus infection is sensed by both Toll-like receptors and retinoic acid-inducible gene-like receptors, which synergize to induce type I interferon production. J Gen Virol 90:74-78. https://doi.org/10.1099/vir.0.005389-0
63. Zhao J, Zeng Y, Xu S, Chen J, Shen G, Yu C, Knipe D, Yuan W, Peng J, Xu W, Zhang C, Xia Z, Feng P. 2016. A viral deamidase targets the helicase domain of RIG-I to block RNA-induced activation. Cell Host Microbe 20:770-784. https://doi.org/10.1016/j.chom.2016.10.011
64. Chiang JJ, Sparrer KMJ, van Gent M, Lassig C, Huang T, Osterrieder N, Hopfner KP, Gack MU. 2017. Viral unmasking of cellular 5S rRNA pseudogene transcripts induces RIG-I-mediated immunity. Nat Immunol 19: 53-62. https://doi.org/10.1038/s41590-017-0005-y
65. White EA, Walther J, Javanbakht H, Howley PM. 2014. Genus beta human papillomavirus E6 proteins vary in their effects on the transactivation of p53 target genes. J Virol 88:8201-8212. https://doi.org/10.1128/JVI .01197-14
66. White EA, Kramer RE, Tan MJ, Hayes SD, Harper JW, Howley PM. 2012. Comprehensive analysis of host cellular interactions with human papillomavirus E6 proteins identifies new E6 binding partners and reflects viral diversity. J Virol 86:13174-13186. https://doi.org/10 .1128/JVI.02172-12
67. van Diemen FR, Kruse EM, Hooykaas MJ, Bruggeling CE, Schurch AC, van Ham PM, Imhof SM, Nijhuis M, Wiertz EJ, Lebbink RJ. 2016. CRISPR/Cas9-mediated genome editing of herpesviruses limits productive and latent infections. PLoS Pathog 12:e1005701. https://doi.org/10.1371/journal .ppat.1005701
68. Spangle JM, Ghosh-Choudhury N, Munger K. 2012. Activation of capdependent translation by mucosal human papillomavirus E6 proteins is dependent on the integrity of the LXXLL binding motif. J Virol 86: 7466-7472. https://doi.org/10.1128/JVI.00487-12
69. Gack MU, Nistal-Villan E, Inn KS, Garcia-Sastre A, Jung JU. 2010. Phosphorylation-mediated negative regulation of RIG-I antiviral activity. J Virol 84:3220-3229. https://doi.org/10.1128/JVI.02241-09
70. Biryukov J, Cruz L, Ryndock EJ, Meyers C. 2015. Native human papillomavirus production, quantification, and infectivity analysis. Methods Mol Biol 1249:317-331. https://doi.org/10.1007/978-1-4939-2013-6_24
71. Conway MJ, Alam S, Ryndock EJ, Cruz L, Christensen ND, Roden RB, Meyers C. 2009. Tissue-spanning redox gradient-dependent assembly of native human papillomavirus type 16 virions. J Virol 83:10515-10526. https://doi.org/10.1128/JVI.00731-09
72. Conway MJ, Cruz L, Alam S, Christensen ND, Meyers C. 2011. Differentiation-dependent interpentameric disulfide bond stabilizes native human papillomavirus type 16. PLoS One 6:e22427. https://doi .org/10.1371/journal.pone.0022427
73. Conway MJ, Cruz L, Alam S, Christensen ND, Meyers C. 2011. Crossneutralization potential of native human papillomavirus N-terminal L2 epitopes. PLoS One 6:e16405. https://doi.org/10.1371/journal .pone.0016405